Enzon Pharmaceuticals, Inc. (ENZN)
USD 0.1
(0.0%)
USD 0.1
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 98 Thousand USD | 152.69% |
| 2022 | -186 Thousand USD | 60.34% |
| 2021 | -469 Thousand USD | 64.23% |
| 2020 | -1.31 Million USD | -33.91% |
| 2019 | -979 Thousand USD | -116.74% |
| 2018 | 5.84 Million USD | 7.42% |
| 2017 | 5.44 Million USD | 583.57% |
| 2016 | -1.12 Million USD | -105.2% |
| 2015 | 21.63 Million USD | -24.86% |
| 2014 | 28.79 Million USD | 58.65% |
| 2013 | 18.15 Million USD | 752.17% |
| 2012 | -2.78 Million USD | 86.6% |
| 2011 | -20.76 Million USD | -111.84% |
| 2010 | 175.4 Million USD | 16323.41% |
| 2009 | 1.06 Million USD | 139.34% |
| 2008 | -2.71 Million USD | -103.27% |
| 2007 | 83.05 Million USD | 289.76% |
| 2006 | 21.3 Million USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 2.87 Million USD | -93.71% |
| 2003 | 45.72 Million USD | -0.18% |
| 2002 | 45.8 Million USD | 297.45% |
| 2001 | 11.52 Million USD | 282.75% |
| 2000 | -6.3 Million USD | -28.7% |
| 1999 | -4.9 Million USD | -36.11% |
| 1998 | -3.6 Million USD | 21.74% |
| 1997 | -4.6 Million USD | 11.54% |
| 1996 | -5.2 Million USD | 17.46% |
| 1995 | -6.3 Million USD | 61.82% |
| 1994 | -16.5 Million USD | 32.93% |
| 1993 | -24.6 Million USD | 12.77% |
| 1992 | -28.2 Million USD | -135.0% |
| 1991 | -12 Million USD | -50.0% |
| 1990 | -8 Million USD | -60.0% |
| 1989 | -5 Million USD | -13.64% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 276 Thousand USD | -13.75% |
| 2024 Q1 | 320 Thousand USD | -52.38% |
| 2024 Q3 | 254 Thousand USD | -7.97% |
| 2023 Q2 | 183 Thousand USD | -7.11% |
| 2023 Q1 | 197 Thousand USD | -40.84% |
| 2023 Q4 | 672 Thousand USD | 109.35% |
| 2023 Q3 | 321 Thousand USD | 75.41% |
| 2023 FY | 1.37 Million USD | 838.17% |
| 2022 Q2 | -123 Thousand USD | 57.73% |
| 2022 Q1 | -291 Thousand USD | -23.83% |
| 2022 FY | -186 Thousand USD | 60.34% |
| 2022 Q4 | 333 Thousand USD | 2320.0% |
| 2022 Q3 | -15 Thousand USD | 87.8% |
| 2021 Q2 | -19 Thousand USD | -272.73% |
| 2021 Q1 | 11 Thousand USD | 102.58% |
| 2021 FY | -469 Thousand USD | 64.23% |
| 2021 Q3 | -226 Thousand USD | -1089.47% |
| 2021 Q4 | -235 Thousand USD | -3.98% |
| 2020 Q3 | -407 Thousand USD | -72.46% |
| 2020 Q4 | -426 Thousand USD | -4.67% |
| 2020 FY | -1.31 Million USD | -33.91% |
| 2020 Q1 | -242 Thousand USD | 7.63% |
| 2020 Q2 | -236 Thousand USD | 2.48% |
| 2019 Q4 | -262 Thousand USD | 19.38% |
| 2019 Q3 | -325 Thousand USD | -1447.62% |
| 2019 FY | -979 Thousand USD | -116.74% |
| 2019 Q2 | -21 Thousand USD | 94.34% |
| 2019 Q1 | -371 Thousand USD | -105.39% |
| 2018 FY | 5.84 Million USD | 7.42% |
| 2018 Q1 | -312 Thousand USD | -167.53% |
| 2018 Q3 | -520 Thousand USD | -152.43% |
| 2018 Q2 | -206 Thousand USD | 33.97% |
| 2018 Q4 | 6.88 Million USD | 1423.46% |
| 2017 Q2 | 4.18 Million USD | 548.84% |
| 2017 Q3 | 153 Thousand USD | -96.34% |
| 2017 Q4 | 462 Thousand USD | 201.96% |
| 2017 FY | 5.44 Million USD | 583.57% |
| 2017 Q1 | 645 Thousand USD | 113.98% |
| 2016 Q4 | -4.61 Million USD | -592.95% |
| 2016 FY | -1.12 Million USD | -105.2% |
| 2016 Q2 | 1.03 Million USD | -31.77% |
| 2016 Q3 | 936 Thousand USD | -9.57% |
| 2016 Q1 | 1.51 Million USD | -87.86% |
| 2015 Q4 | 12.49 Million USD | 788.92% |
| 2015 Q2 | 3.78 Million USD | -47.27% |
| 2015 FY | 21.63 Million USD | -24.86% |
| 2015 Q3 | -1.81 Million USD | -147.96% |
| 2015 Q1 | 7.17 Million USD | 23.67% |
| 2014 Q4 | 5.8 Million USD | -23.6% |
| 2014 Q1 | 8.52 Million USD | 55.52% |
| 2014 Q2 | 6.88 Million USD | -19.23% |
| 2014 Q3 | 7.59 Million USD | 10.32% |
| 2014 FY | 28.79 Million USD | 58.65% |
| 2013 Q1 | 2.39 Million USD | 146.34% |
| 2013 Q4 | 5.47 Million USD | -1.49% |
| 2013 Q3 | 5.56 Million USD | 17.86% |
| 2013 Q2 | 4.71 Million USD | 97.45% |
| 2013 FY | 18.15 Million USD | 752.17% |
| 2012 FY | -2.78 Million USD | 86.6% |
| 2012 Q4 | -5.15 Million USD | -223.54% |
| 2012 Q3 | 4.17 Million USD | 672.7% |
| 2012 Q2 | -729 Thousand USD | 31.93% |
| 2012 Q1 | -1.07 Million USD | 78.67% |
| 2011 Q4 | -5.02 Million USD | 44.85% |
| 2011 Q3 | -9.1 Million USD | -28.82% |
| 2011 Q2 | -7.06 Million USD | -1739.91% |
| 2011 Q1 | 431 Thousand USD | 105.02% |
| 2011 FY | -20.76 Million USD | -111.84% |
| 2010 Q1 | 199.8 Million USD | 35526.77% |
| 2010 FY | 175.4 Million USD | 16323.41% |
| 2010 Q2 | -5.62 Million USD | -102.81% |
| 2010 Q3 | -8.35 Million USD | -48.59% |
| 2010 Q4 | -8.58 Million USD | -2.8% |
| 2009 Q4 | -564 Thousand USD | -524.06% |
| 2009 Q3 | 133 Thousand USD | 102.63% |
| 2009 Q2 | -5.06 Million USD | -181.97% |
| 2009 Q1 | 6.18 Million USD | 1426.18% |
| 2009 FY | 1.06 Million USD | 139.34% |
| 2008 Q4 | -466 Thousand USD | 76.93% |
| 2008 Q3 | -2.02 Million USD | -15.76% |
| 2008 Q1 | 1.51 Million USD | 465.67% |
| 2008 Q2 | -1.74 Million USD | -215.11% |
| 2008 FY | -2.71 Million USD | -103.27% |
| 2007 Q4 | 268 Thousand USD | -99.69% |
| 2007 Q2 | -3.04 Million USD | -64.27% |
| 2007 FY | 83.05 Million USD | 289.76% |
| 2007 Q3 | 87.53 Million USD | 2975.49% |
| 2007 Q1 | -1.85 Million USD | 86.4% |
| 2006 FY | 21.3 Million USD | 0.0% |
| 2006 Q4 | -13.62 Million USD | -708.76% |
| 2006 Q3 | 2.23 Million USD | -79.63% |
| 2006 Q2 | 10.98 Million USD | -49.39% |
| 2006 Q1 | 21.7 Million USD | 0.0% |
| 2005 FY | - USD | -100.0% |
| 2005 Q4 | - USD | 100.0% |
| 2005 Q3 | -5.76 Million USD | 93.13% |
| 2005 Q2 | -83.95 Million USD | -1734.24% |
| 2005 Q1 | -4.57 Million USD | -760.34% |
| 2004 Q1 | 5.06 Million USD | 118.46% |
| 2004 FY | 2.87 Million USD | -93.71% |
| 2004 Q3 | -544 Thousand USD | 92.56% |
| 2004 Q4 | -532 Thousand USD | 2.21% |
| 2004 Q2 | -7.31 Million USD | -244.33% |
| 2003 Q3 | 2.8 Million USD | -93.09% |
| 2003 Q2 | 40.55 Million USD | 431.2% |
| 2003 Q1 | 7.63 Million USD | 150.08% |
| 2003 Q4 | 2.31 Million USD | -17.3% |
| 2003 FY | 45.72 Million USD | -0.18% |
| 2002 Q1 | 12.16 Million USD | 40.73% |
| 2002 Q2 | 20.76 Million USD | 70.65% |
| 2002 Q4 | -15.24 Million USD | -219.25% |
| 2002 Q3 | 12.78 Million USD | -38.43% |
| 2002 FY | 45.8 Million USD | 297.45% |
| 2001 Q4 | 8.64 Million USD | 104.38% |
| 2001 FY | 11.52 Million USD | 282.75% |
| 2001 Q1 | 5.5 Million USD | 157.7% |
| 2001 Q2 | 3.3 Million USD | -39.94% |
| 2001 Q3 | 4.23 Million USD | 27.87% |
| 2000 Q4 | 2.13 Million USD | 266.82% |
| 2000 Q1 | -1.68 Million USD | -12.33% |
| 2000 Q2 | -1.16 Million USD | 31.08% |
| 2000 Q3 | 582.7 Thousand USD | 150.18% |
| 2000 FY | -6.3 Million USD | -28.7% |
| 1999 Q2 | -1.5 Million USD | -7.14% |
| 1999 FY | -4.9 Million USD | -36.11% |
| 1999 Q3 | -2 Million USD | -33.33% |
| 1999 Q4 | -1.5 Million USD | 25.0% |
| 1999 Q1 | -1.4 Million USD | -55.56% |
| 1998 Q3 | -1.1 Million USD | 52.17% |
| 1998 FY | -3.6 Million USD | 21.74% |
| 1998 Q2 | -2.3 Million USD | -35.29% |
| 1998 Q4 | -900 Thousand USD | 18.18% |
| 1998 Q1 | -1.7 Million USD | -750.0% |
| 1997 Q1 | -2 Million USD | -185.71% |
| 1997 Q2 | -1.2 Million USD | 40.0% |
| 1997 FY | -4.6 Million USD | 11.54% |
| 1997 Q4 | -200 Thousand USD | -128.57% |
| 1997 Q3 | 700 Thousand USD | 158.33% |
| 1996 Q2 | -1 Million USD | 50.0% |
| 1996 Q1 | -2 Million USD | -1900.0% |
| 1996 Q4 | -700 Thousand USD | 0.0% |
| 1996 FY | -5.2 Million USD | 17.46% |
| 1996 Q3 | -700 Thousand USD | 30.0% |
| 1995 FY | -6.3 Million USD | 61.82% |
| 1995 Q3 | -1.9 Million USD | -280.0% |
| 1995 Q2 | -500 Thousand USD | 28.57% |
| 1995 Q1 | -700 Thousand USD | 79.41% |
| 1995 Q4 | -100 Thousand USD | 94.74% |
| 1994 Q1 | 700 Thousand USD | 111.86% |
| 1994 Q2 | -5.2 Million USD | -842.86% |
| 1994 Q3 | -1.7 Million USD | 67.31% |
| 1994 Q4 | -3.4 Million USD | -100.0% |
| 1994 FY | -16.5 Million USD | 32.93% |
| 1993 Q4 | -5.9 Million USD | 3.28% |
| 1993 Q1 | -7 Million USD | -12.9% |
| 1993 Q2 | -6.2 Million USD | 11.43% |
| 1993 FY | -24.6 Million USD | 12.77% |
| 1993 Q3 | -6.1 Million USD | 1.61% |
| 1992 Q4 | -6.2 Million USD | -19.23% |
| 1992 Q1 | -5.5 Million USD | 54.92% |
| 1992 FY | -28.2 Million USD | -135.0% |
| 1992 Q2 | -7.8 Million USD | -41.82% |
| 1992 Q3 | -5.2 Million USD | 33.33% |
| 1991 Q3 | -2.7 Million USD | 15.63% |
| 1991 FY | -12 Million USD | -50.0% |
| 1991 Q1 | -3.5 Million USD | 0.0% |
| 1991 Q2 | -3.2 Million USD | 8.57% |
| 1991 Q4 | -12.2 Million USD | -351.85% |
| 1990 Q2 | - USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 FY | -8 Million USD | -60.0% |
| 1989 Q3 | - USD | 0.0% |
| 1989 Q4 | - USD | 0.0% |
| 1989 Q2 | - USD | 0.0% |
| 1989 Q1 | - USD | 0.0% |
| 1989 FY | -5 Million USD | -13.64% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 107.338% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 101.403% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 99.815% |
| Nascent Biotech, Inc. | -2.08 Million USD | 104.694% |
| Rebus Holdings, Inc. | -1.02 Million USD | 109.608% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 99.85% |
| Qrons Inc. | -789.34 Thousand USD | 112.415% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 115.496% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 100.157% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 123.587% |
| Skye Bioscience, Inc. | -37.64 Million USD | 100.26% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 100.131% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 101.49% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 135.845% |
| SQZ Biotechnologies Company | -79.46 Million USD | 100.123% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 103.388% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 105.383% |
| Mesoblast Limited | -87.95 Million USD | 100.111% |
| Marizyme, Inc. | -65.34 Million USD | 100.15% |
| Genus plc | 7.9 Million USD | 98.759% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 100.9% |
| Pharming Group N.V. | -10.54 Million USD | 100.929% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 104.517% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 102.641% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 101.108% |
| ContraFect Corporation | -65.15 Million USD | 100.15% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 102.006% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 105.673% |
| IMV Inc. | -36.48 Million USD | 100.269% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 101.216% |
| MultiCell Technologies, Inc. | -380.07 USD | 25884.724% |
| ONE Bio Corp. | 8.67 Million USD | 98.871% |
| Accustem Sciences Inc. | -3.74 Million USD | 102.616% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 100.19% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 107.734% |
| Q BioMed Inc. | -2.05 Million USD | 104.776% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 102.625% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 104.116% |
| Biomind Labs Inc. | -1.21 Million USD | 108.07% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 100.164% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 103.159% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 101.24% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 105.028% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 754.38% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 100.617% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 101.685% |
| GB Sciences, Inc. | -1.36 Million USD | 107.197% |
| Alpha Cognition Inc. | -13.77 Million USD | 100.712% |
| HST Global, Inc. | -146.21 Thousand USD | 167.027% |
| CSL Limited | 2.64 Billion USD | 99.996% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 105.585% |
| Halberd Corporation | -79.67 Thousand USD | 222.998% |
| Enzolytics Inc. | -2.17 Million USD | 104.502% |
| Agentix Corp. | -1.37 Million USD | 107.131% |
| Resverlogix Corp. | -3.61 Million USD | 102.715% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 103.09% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -295.05 Million USD | 100.033% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 98.585% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 102.467% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 103.238% |
| AVAX Technologies, Inc. | -6.41 Million USD | 101.528% |
| Zenith Capital Corp. | -10.59 Million USD | 100.925% |
| Genscript Biotech Corporation | -95.47 Million USD | 100.103% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 521.65% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 102.364% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 262.143% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 104.888% |
| Kadimastem Ltd | -3.3 Million USD | 102.963% |
| Helix BioMedix, Inc. | -1.05 Million USD | 109.28% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 102.566% |
| BioStem Technologies, Inc. | -8.48 Million USD | 101.155% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 122.204% |
| LadRx Corporation | 400.44 Thousand USD | 75.527% |
| Cell Source, Inc. | -5.32 Million USD | 101.842% |
| Regen BioPharma, Inc. | 1.02 Million USD | 90.425% |
| Regen BioPharma, Inc. | 1.02 Million USD | 90.425% |
| NovAccess Global Inc. | -4.76 Million USD | 102.055% |
| Affymax, Inc. | -14.42 Million USD | 100.679% |
| Itoco Inc. | -1.86 Million USD | 105.243% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 102.206% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 105.872% |
| Mobile Lads Corp. | -2.26 Million USD | 104.33% |
| CytoDyn Inc. | -49.84 Million USD | 100.197% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 223.999% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 142.959% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 110.409% |
| SYBLEU INC | -180.3 Thousand USD | 154.353% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 106.077% |
| International Stem Cell Corporation | -131 Thousand USD | 174.809% |
| Bioxytran, Inc. | -4.28 Million USD | 102.29% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 280.572% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 103.873% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 100.204% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 104.636% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 112.55% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 103.093% |
| Neutra Corp. | -233.46 Thousand USD | 141.976% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 100.483% |
| PureTech Health plc | -65.69 Million USD | 100.149% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 100.461% |
| IXICO plc | -1.17 Million USD | 108.319% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 100.987% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 100.172% |
| CSL Limited | 2.64 Billion USD | 99.996% |
| Cellectis S.A. | -103.17 Million USD | 100.095% |